SEROLOGICAL AND METABOLIC CHARACTERIZATION OF THE COHORT MACAENSES CITIZENS AFTER THE 1st AND 2nd DOSES OF THE ASTRAZENECA VACCINE TECHNOLOGY

Vol 1, 2023 - 168864
Trabalho
Favoritar este trabalho
Como citar esse trabalho?
Resumo

Beginning in 2019, starting in China, a new coronavirus called SARS-CoV-2 began circulating in the world and, starting in China, and within a short time it spread and reached large proportions, causing a pandemic. SARS-CoV-2 is an enveloped virus with single-stranded RNA. It is the causative agent of COVID-19 and causes respiratory, enteric, hepatic and neurologic disease associated with acute and severe infections. After the virus genome was published in 2020 several institutions started research for the development of vaccines. AstraZeneca`s vaccine, which consists of a monovalent technology (recombinant) vaccine composed of a single replication-deficient adenovirus vector expressing the SARS CoV-2 S glycoprotein, was included in the study.

Compartilhe suas ideias ou dúvidas com os autores!

Sabia que o maior estímulo no desenvolvimento científico e cultural é a curiosidade? Deixe seus questionamentos ou sugestões para o autor!

Faça login para interagir

Tem uma dúvida ou sugestão? Compartilhe seu feedback com os autores!

Eixo Temático
  • 9 - Biologia e Doenças Respiratórias